The Role of Biotechnology in Europe's Responsible Innovation - Judging panel
|Latest News||Programme||SME Award||Location|
Dr Andrea Rappagliosi
Vice President European Government Affairs &
Head of Brussels Office GlaxoSmithKline
Dr Rappagliosi was appointed Chairman of EuropaBio in June 2009.
In April 2009, Andrea joined GlaxoSmithKline as Vice President European Government Affairs & Head of Brussels Office. His work at GSK was preceded by a decade of experience at Merck Serono International where he was Vice President of Health Policy and Market Access in Europe. From 1995 to 1999, he was Public Affairs Director at Baxter Healthcare, part of the European Public Affairs team.
From 2005 to 2008, Dr Rappagliosi was a member of the European Commission High Level Pharmaceutical Forum representing EuropaBio, the European Association for Bioindustry. He sits on the Board of the Foundation of the European Platform for Patients Organizations, Science & Industry (EPPOSI) and is member of HTAi (the International Society of Health Technology Assessment) and founding member of its Policy Forum. In addition, he has been Industry representative at the EMEA/COMP (European Medicines Evaluation Agency/ Committee for Orphan Medicinal Products) Working Group with Interested Parties in the first two terms 2000 to 2005. Dr Rappagliosi is a member of the British Institute of International and Comparative Law and is a member of the Editorial Board of the Journal of Commercial Biotechnology. e change.
Member of the European Parliament (EPP)
Paul Rübig is an Austrian politician and a Member of the European Parliament since 1996. He is a member of the Bureau of the European People's Party and his work in the EP focuses mainly on Committee on Industry, Research and Energy.
Since 2003 he has been the President of SME Global, which is an association that aims at establishing global network for small and medium enterprises.
He is also the chairman of STOA, Science and Technology Options Assessment panel, devoted to all issues related to technology assessment and science assessment. STOA increasingly focuses upon round-table expert discussions, conferences and workshops with external experts from consultancies, universities or researchers.
Thomas Reese Saylor
Chief Executive Officer, Arecor Ltd. representing BIA
Chair of the SME Platform
In 2009 EuropaBio launched its SME platform, appointing Tom Saylor as its chair. The SME Platform brings together various stakeholders, including CEOs of SMEs, National Biotech Associations, venture capitalists and private banks, European financial institutions, and representatives from the EU, and aims highlight the challenges and financial constraints that biotech SMEs face as well as develop policy recommendations to optimise EU and member state funding instruments for biotech SMEs.
Tom has a background in management, strategy development, deal negotiation and fundraising for entrepreneurial biopharmaceutical companies. He currently works as the CEO of Arecor Ltd, a pharmaceutical company which Arecor Ltd. develops stabilization technology solutions for pharmaceutical and biotech companies developing recombinant proteins and vaccines for application in drugs, medical devices, or diagnostics.
He has previously held key board positions for Sirus Pharmaceuticals Limited, Lotus Healthcare Corporation and Cell Systems Limited. Tom was also a principal trade negotiator for the United States during the Tokyo Round.
Tom holds an MBA from Harvard University, doctoral studies in molecular biology at the Max Planck Institute for Psychiatry in Munich and a degree in molecular biology from the Georgia Institute of Technology.
Professor of Business Economics and Game Theory, KULeuven (BE)
Prof Dr. Reinhilde Veugelers is a full-time professor at KULeuven (BE) at the Faculty of Economics and Business, where she teaches international business economics and game theory. From 2004-2008, she was on academic leave, as advisor at the European Commission (BEPA Bureau of European Policy Analysis). She is currently a Senior Fellow at Bruegel, a CEPR Research Fellow. She is also co-promoting ECOOM, the Flemish Center for R&D Monitoring. She was a visiting scholar at Northwestern University’s Kellogg Graduate School of Management, Sloan School of Management, MIT, Stern Business School, NYU (US), UCL (BE), ECARES/ ULBrussels, (BE) Paris I (FR) UPF & UAB-Barcelona (ES), UMaastricht (NL) and is currently visiting faculty at the MSI program of the Barcelona UPF-UAB Graduate School.
With her research concentrated in the fields of industrial organisation, international economics and strategy, innovation and science, she has authored numerous publications in leading international journals. Her research combines analytical frameworks, using micro-economics, game theory and economics of information models, with empirical, mostly econometric testing on large datasets. Specific recent topics include incentives for innovation activities, international technology transfers through MNEs, impact on local R&D of multinational competition, internal and external technology sourcing, alliances and their stability, inter-company technology transfers through cooperation, young innovative companies, industry science links and their impact on firm’s innovative productivity, performance of technology transfer offices at universities, designing university spin-off contracts, explaining scientific productivity: persistency and skewness, researchers’ international mobility. Recent policy topics include: university governance and higher education reforms, financing innovation for young radical innovators, innovation policy indicators, innovation strategies for catching-up countries, and innovation for climate change.